Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2016

View Archived Issues

Pfizer discloses vanin-1 inhibitors

A-000830 is a promising novel small-molecule inhibitor of ecto-nucleotidase CD73

HTL-001 is highly cytotoxic to prostate and breast cancer cells in vitro and in vivo

Ono gains access to Ligand Pharmaceuticals' OmniAb platform

Bantam Pharmaceutical patents mRNA translation initiation inhibitors

Lead Pharma Cel Models and Sanofi disclose RORgamma modulators

GlaxoSmithKline and University of Dundee describe antiparasitic agents

Genticel and Genkyotex sign contribution agreement

First patient enrolled in LTX-315 anti-PD-1 combination study

RespireRx Pharmaceuticals announces positive results from phase IIb PACE study

RO-689921 is well tolerated in patients with solid tumors

Neothetics initiates phase II trial of LIPO-202 for the reduction of submental subcutaneous fat

Strongbridge Biopharma acquires U.S. rights to Keveyis from Taro

First patient enrolled in BioHaven's phase IIb/III study of BHV-4157

FDA grants approval to Spinraza for treatment of spinal muscular atrophy

FDA accepts betrixaban NDA for priority review, EMA validates MAA

Pluristem and NYBC to collaborate in developing PLX-R18 cell therapy

Tokai Pharmaceuticals and Otic Pharma enter definitive share purchase agreement

Biocartis announces RAS biomarker testing collaboration with Amgen in Europe

Phase IIb data support advancement of linaclotide colonic release-1 in IBS-C

Dipexium and PLx Pharma enter merger agreement

Synergy Pharmaceuticals reports topline results of second pivotal study of plecanatide in IBS-C

TiGenix submits responses to EMA regarding Cx-601 MAA

MSD seeks approval of additional indication for Keytruda in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...